Medicamen Biotech Ltd. engages in the manufacture and marketing of pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm is engaged in manufacturing pharmaceutical formulations products. The firm manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The firm is primarily focused on oncology therapeutics. The firm is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. The firm's oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, Nilotinib HCI, Oxaliplatin, Pazopanib, Pomalidomide and Tegafur. The firm has two manufacturing plants at Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The firm's wholly owned subsidiary is OPAL Pharmaceuticals Pty Ltd.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.